https://assets.capyfin.com/instruments/678fdc13234e27009c5d586d.png avatar
Ecolab
🇺🇸 NYSE:ECL
View Company
OverviewEarningsDividends
•
Jun 30, 2020

Ecolab Q2 2020 Earnings Report

Ecolab's performance was significantly impacted by COVID-19, with strong growth in Healthcare and Life Sciences offset by declines in Institutional and Other segments. The separation of ChampionX business also affected the results.

Key Takeaways

Ecolab's second quarter results were impacted by COVID-19, with a 15% decrease in reported sales. Adjusted EPS from continuing operations was $0.65, a 49% decrease. The Healthcare and Life Sciences segment showed strong growth, while the Institutional segment was heavily impacted by COVID-19 shutdowns.

Reported sales from continuing operations decreased by 15%.

Reported diluted EPS from continuing operations decreased by 63% to $0.44.

Adjusted diluted EPS from continuing operations decreased by 49% to $0.65.

Free cash flow from continuing operations was $229 million.

Total Revenue
$2.69B
Previous year: $3.76B
-28.5%
EPS
$0.65
Previous year: $1.42
-54.2%
Gross Profit
$1.05B
Previous year: $1.55B
-32.3%
Cash and Equivalents
$1.37B
Previous year: $85.7M
+1497.4%
Free Cash Flow
$275M
Previous year: $356M
-22.7%
Total Assets
$18.1B
Previous year: $20.8B
-13.2%

Ecolab

Ecolab

Ecolab Revenue by Segment

Forward Guidance

Due to the uncertain outlook regarding the full extent of COVID-19’s impact on the global economy and its longevity, Ecolab is not providing either quarterly or annual earnings forecasts.

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Ecolab